



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Guoxu Zhang
✉ zhangguoxu_502@163.com
Hongwu Sun
✉ sunhongwu2001@163.com

[†]These authors have contributed
equally to this work and share
first authorship

RECEIVED 02 June 2025
ACCEPTED 03 June 2025
PUBLISHED 19 June 2025

CITATION

Tong Y, Lu G, Wang Z, Hao S, Zhang G and
Sun H (2025) Correction: Tubeimuside I
improves the efficacy of a therapeutic
Fusobacterium nucleatum dendritic cell-
based vaccine against colorectal cancer.
Front. Immunol. 16:1639717.
doi: 10.3389/fimmu.2025.1639717

COPYRIGHT

© 2025 Tong, Lu, Wang, Hao, Zhang and Sun.
This is an open-access article distributed under
the terms of the [Creative Commons Attribution
License \(CC BY\)](#). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or reproduction
is permitted which does not comply with
these terms.

Correction: Tubeimuside I improves the efficacy of a therapeutic *Fusobacterium nucleatum* dendritic cell-based vaccine against colorectal cancer

Yanan Tong^{1†}, Guoxiu Lu^{2†}, Zhiguo Wang¹, Shanhu Hao¹,
Guoxu Zhang^{1*} and Hongwu Sun^{3*}

¹Department of Nuclear Medicine, General Hospital of Northern Theater Command, Shenyang, China,

²College of Medicine and Biological Information Engineering, Northeastern University, Shenyang, Liaoning, China, ³Department of Microbiology and Biochemical Pharmacy, National Engineering Research Center of Immunological Products, College of Pharmacy, Third Military Medical University, Chongqing, China

KEYWORDS

colorectal cancer, *F. nucleatum*, tubeimuside I, dendritic cells, vaccine

A Correction on

Tubeimuside I improves the efficacy of a therapeutic *Fusobacterium nucleatum* dendritic cell-based vaccine against colorectal cancer

by Tong Y, Lu G, Wang Z, Hao S, Zhang G and Sun H (2023). *Front. Immunol.* 14:1154818.
doi: 10.3389/fimmu.2023.1154818

Author Guoxiu Lu was erroneously assigned to Affiliation 1 Department of Nuclear Medicine, General Hospital of Northern Theater Command, Shenyang, China. This affiliation has now been removed for author Guoxiu Lu.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.